Myeloproliferative Neoplasms (MPN): Recent Advances, Current Practices and Future Perspectives

Dear Colleagues,

During the last two decades, our understanding of the pathogenesis of Ph-ve chronic myeloproliferative neoplasms.

(MPN: polycythemia vera, essential thrombocythemia and myelofibrosis) has increased significantly. Treatment of patients with MPN has also improved with the introduction of long-acting interferons for cytoreduction and use of JAK-2 inhibitor therapy for symptom relief in patients with myelofibrosis. Risk assessment and prevention of thrombosis have been the focus for several studies. Despite these advances, there are several areas of uncertainty in the management of MPN patients, e.g., dosage schedules for hydroxyurea therapy; indication for the use of aspirin for thromboprophylaxis; dosage schedules for aspirin prophylaxis; choice of JAK-2 inhibitor therapy and the use of cytoreductive therapy in conjunction with JAK-2 inhibitor therapy in patients with myelofibrosis.

The proposed Special Issue aims to record all the recent developments and current management practices, as well as outline possible areas of future research to improve clinical outcomes in patients with MPN.

Suggested Topics:

• Pathogenesis of MPN and diagnosis in the era of molecular studies;
• Risk assessment for thrombosis and initiation of thromboprophylaxis;
• Prognosis and treatment of patients with polycythemia vera;
• Prognosis and treatment of patients with essential thrombocythemia;
• Prognosis and treatment of patients with myelofibrosis;
• Long-term complications in patients with MPN.

Prof. Dr. Arumugam Manoharan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.